Cancer Family
Carcinoma
CI-CAN-00000114Explore in graph →
7,363 active trials118 approved drugs1,149 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000114Explore in graph →
Clinical trials
25,720 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (3,404)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04181060 | Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer | recruiting | Phase 3 | 300 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT04267848 | Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO]) | recruiting | Phase 3 | 1,210 | National Cancer Institute (NCI)NIH | 2 | Sep 29, 2026 |
| clinicaltrials |
| NCT04628767 | Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer | recruiting | Phase 2 / Phase 3 | 131 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05256225 | Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma | recruiting | Phase 3 | 360 | National Cancer Institute (NCI)NIH | 3 | Sep 29, 2026 | clinicaltrials |
| NCT05987241 | Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study | recruiting | Phase 2 / Phase 3 | 992 | National Cancer Institute (NCI)NIH | 2 | Sep 29, 2026 | clinicaltrials |
| NCT06058377 | Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer | recruiting | Phase 3 | 3,680 | National Cancer Institute (NCI)NIH | 2 | Sep 29, 2026 | clinicaltrials |
| NCT06203600 | Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial | recruiting | Phase 2 / Phase 3 | 224 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT06498635 | Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial | recruiting | Phase 3 | 306 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT06524544 | A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer | recruiting | Phase 3 | 320 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT06589804 | Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment | recruiting | Phase 3 | 158 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT06627712 | SBRT Combined With PD-1 Inhibitor and Chemotherapy in Early-stage TNBC | recruiting | Phase 3 | 318 | West China HospitalOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT06881784 | Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)(RASolve 301) | recruiting | Phase 3 | 590 | Revolution Medicines, Inc.INDUSTRY | 19 | Sep 29, 2026 | clinicaltrials |
| NCT07011719 | Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma | recruiting | Phase 3 | 720 | Arcus Biosciences, Inc.INDUSTRY | 17 | Sep 29, 2026 | clinicaltrials |
| NCT07061977 | Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer | recruiting | Phase 3 | 336 | National Cancer Institute (NCI)NIH | 2 | Sep 29, 2026 | clinicaltrials |
| NCT07198074 | Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer | recruiting | Phase 3 | 255 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07388524 | Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial | recruiting | Phase 3 | 336 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07472517 | DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy | recruiting | Phase 3 | 670 | Boehringer IngelheimINDUSTRY | 42 | Sep 29, 2026 | clinicaltrials |
| NCT07554339 | A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015) | recruiting | Phase 3 | 310 | Merck Sharp & Dohme LLCINDUSTRY | 17 | Sep 29, 2026 | clinicaltrials |
| NCT06623422 | A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009) | recruiting | Phase 3 | 680 | Merck Sharp & Dohme LLCINDUSTRY | 31 | Sep 28, 2026 | clinicaltrials |
| NCT06919965 | A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer(MoonRISe-3) | recruiting | Phase 3 | 220 | Janssen Research & Development, LLCINDUSTRY | 15 | Sep 28, 2026 | clinicaltrials |
| NCT06931717 | A Clinical Study to Assess the Efficacy of Adjuvant Immunotherapy With Cemiplimab in Patients With Surgically Removed Non-small Cell Lung Cancer Who Have Not Received Prior Chemotherapy(ARCH) | recruiting | Phase 3 | 390 | ETOP IBCSG Partners FoundationNETWORK | 9 | Sep 28, 2026 | clinicaltrials |
| NCT06997497 | A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012) | recruiting | Phase 3 | 477 | Merck Sharp & Dohme LLCINDUSTRY | 29 | Sep 28, 2026 | clinicaltrials |
| NCT07190248 | A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007) | recruiting | Phase 3 | 675 | Merck Sharp & Dohme LLCINDUSTRY | 30 | Sep 28, 2026 | clinicaltrials |
| NCT07226999 | Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer | recruiting | Phase 2 / Phase 3 | 550 | PfizerINDUSTRY | 10 | Sep 28, 2026 | clinicaltrials |
| NCT07391774 | Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial | recruiting | Phase 3 | 1,978 | National Cancer Institute (NCI)NIH | 2 | Sep 28, 2026 | clinicaltrials |
| NCT07392892 | Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer | recruiting | Phase 2 / Phase 3 | 840 | PfizerINDUSTRY | 10 | Sep 28, 2026 | clinicaltrials |
| NCT07498907 | Disitamab Vedotin Plus Radiotherapy for Adjuvant Treatment of HER2-Expressing Cisplatin-Ineligible Upper Tract Urothelial Carcinoma(LUXUS41) | recruiting | Phase 3 | 192 | Peking University First HospitalOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07513376 | A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)(INTerpath-014) | recruiting | Phase 3 | 876 | Merck Sharp & Dohme LLCINDUSTRY | 18 | Sep 28, 2026 | clinicaltrials |
| NCT07621718 | Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )(RASolute 305) | recruiting | Phase 3 | 670 | Revolution Medicines, Inc.INDUSTRY | 2 | Sep 28, 2026 | clinicaltrials |
| NCT04892173 | JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC | recruiting | Phase 3 | 500 | Johnson & Johnson Enterprise Innovation Inc.INDUSTRY | 27 | Sep 25, 2026 | clinicaltrials |
| NCT06136650 | A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004) | recruiting | Phase 3 | 1,314 | Merck Sharp & Dohme LLCINDUSTRY | 39 | Sep 25, 2026 | clinicaltrials |
| NCT06170788 | Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)(TroFuse-007) | recruiting | Phase 3 | 614 | Merck Sharp & Dohme LLCINDUSTRY | 26 | Sep 25, 2026 | clinicaltrials |
| NCT06312137 | A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)(TroFuse-019) | recruiting | Phase 3 | 780 | Merck Sharp & Dohme LLCINDUSTRY | 31 | Sep 25, 2026 | clinicaltrials |
| NCT06319820 | A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer(MoonRISe-1) | recruiting | Phase 3 | 641 | Janssen Research & Development, LLCINDUSTRY | 20 | Sep 25, 2026 | clinicaltrials |
| NCT06393374 | Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012) | recruiting | Phase 3 | 1,530 | Merck Sharp & Dohme LLCINDUSTRY | 31 | Sep 25, 2026 | clinicaltrials |
| NCT06618664 | A Clinical Study of SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Sintilimab Combined With Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma (KYLIN-02) | recruiting | Phase 3 | 590 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Sep 25, 2026 | clinicaltrials |
| NCT06629779 | A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer. | recruiting | Phase 3 | 900 | PfizerINDUSTRY | 27 | Sep 25, 2026 | clinicaltrials |
| NCT06841354 | A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) | recruiting | Phase 3 | 1,000 | Merck Sharp & Dohme LLCINDUSTRY | 35 | Sep 25, 2026 | clinicaltrials |
| NCT06868277 | A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer(ARTEMIDELung04) | recruiting | Phase 3 | 830 | AstraZenecaINDUSTRY | 27 | Sep 25, 2026 | clinicaltrials |
| NCT06966700 | A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) | recruiting | Phase 3 | 2,400 | Merck Sharp & Dohme LLCINDUSTRY | 40 | Sep 25, 2026 | clinicaltrials |
| NCT06989437 | A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue | recruiting | Phase 2 / Phase 3 | 982 | PfizerINDUSTRY | 21 | Sep 25, 2026 | clinicaltrials |
| NCT07271355 | Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial | recruiting | Phase 3 | 129 | City of Hope Medical CenterOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07276399 | A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer(OrigAMI-5) | recruiting | Phase 3 | 500 | Janssen Research & Development, LLCINDUSTRY | 22 | Sep 25, 2026 | clinicaltrials |
| NCT07489495 | A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034) | recruiting | Phase 3 | 758 | Merck Sharp & Dohme LLCINDUSTRY | 19 | Sep 25, 2026 | clinicaltrials |
| NCT07562152 | Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma(MAPKeeper 301) | recruiting | Phase 3 | 510 | Immuneering CorporationINDUSTRY | 4 | Sep 25, 2026 | clinicaltrials |
Data updated 16 hours agoSource updated Sep 29, 2026source: clinicaltrials